Amylin Pharmaceuticals Inc. (AMLN) announced that its fourth-quarter GAAP net loss was $50.3 million, or $0.35 per share, compared to a loss $105.2 million or $0.76 per share for the same period in 2008.
The company said that prior year results have been adjusted to reflect an accounting change whereby research and development costs that were reimbursed by the Company's collaborative partners are recorded as a reduction of research and development expense. These costs were previously recorded as "Revenues under collaborative agreements."
Non-GAAP operating loss was $17.0 million, compared to $20.2 million for the same period in 2008. Net loss excluding restructuring charges was $44.7 million, or $0.32 per share, compared to $50.3 million, or $0.37 per share for the same period in 2008.
Total revenues were $185.53 million, compared to $185.99 million in the year ago quarter.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.30 per share on revenues of $219.38 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.